Pinned Tweet
$OPEN updated. Chart prophecy of $88 delayed, but prophecy of $30+-5 stays solid in 9-12 mos, min PT is $10 in June
Kaz gets rid of some of inv. saved int.& inv. cost. Q4 25 revs blasted off. Congrats @nejatian @rabois. @jeffye888 @founderwithadhd @mikealfred
A good one
黄仁勋已经把话放出去了:
董事会点头,他就回来。
可这事不归19万请愿管,
不归特朗普管,
也不归马斯克管。
只归10个人管。
6个人举手,他当天就能官复原职。
这10票长什么样?
我一张一张拆给你看。
先说清:没有一个董事公开表过态,
11月11号晚上那场会投了几比几,也没披露。
下面的站位,
是按每个人的持股、背景、这几天干的事推出来的。
推得对不对,往下看账。
一、黄仁勋要回来,先走哪几道门?
第一道门:这事根本不在股东大会上。
CEO在美国公司法里是董事会任命的高管,
股东选的是董事,不是CEO。
请愿签19万人,一票都不算。
第二道门:先得有人把会开起来。
主席、临时CEO、或者任意2名董事,
都能召集董事会,提前24小时通知就行。
也就是说,想推这事的人,连主席那关都能绕过去开会。
第三道门,也是最硬的一道:票数。
现在董事会在任10人,
开会至少要到6人,
任命CEO要“在任董事过半”同意。
10个人过半,就是6票。
5比5,不行。
有人弃权,门槛也不降,还是要6张赞成票。
第四道门:CEO和董事是两个位子。
6票能把黄仁勋送回CEO办公室,
但他辞掉的董事席,不会自动回来。
董事席要么董事会另行投票补上,
要么等2027年股东大会重新选。
所以真要回,第一步大概率是:
先回CEO,不回董事会,更不回主席。
第五道门:投完还没完。
薪酬委员会给他定待遇,
公司要在4个工作日内向证监会发8-K公告,
把任命正式告诉全市场。
还有一条野路子,就是阿克曼说的那条:
凑够15%的股份、且连续持有一年,
可以要求开特别股东会。
但特别股东会也选不了CEO,
只能换董事,再让新董事会任命。
老黄自己只有3.58%的股份,
贝莱德7.43%加先锋7.31%,是14.74%,
差一口气,
加上老黄才18.32%,过线。
这条路是用来吓董事会的,不是用来直接投票的。
门讲完了。
真正的戏,在这10个人身上。
二、10个董事,三个阵营
先看一笔总账。
这10个人分成三堆:4个、4个、2个。
同意派4个人,手里一共7410万股。
反对派4个人,手里一共55.8万股。
中间2个人,手里一共4万股。
钱最多的想他回来,
钱最少的守着规矩,
而手里钱最少最少的两个人,
偏偏决定最后的结果。
1. 马克·史蒂文斯,持股3410万股。
红杉出身,1993年英伟达种子轮的出资人。
他一个人的持股,值五十多亿美元。
股价跌,他疼得最厉害。
这种人投票不用讲情怀,
账本自己会说话。
2. 坦奇·考克斯,持股3060万股。
Sutter Hill出身,
跟史蒂文斯同一年进的钱、进的董事会,
在英伟达坐了33年。
他和史蒂文斯两个人,
占了全体外部董事持股的86%。
老黄是他们这辈子最成功的一笔投资,
他们没有理由看着这笔投资被一个丑闻清零。
3. 哈维·琼斯,持股700万股,现任主席。
他是老黄30岁时的导师,
当年创始人亲自请他进的董事会。
按钱和交情,他都该在同意派。
但他是同意派里最别扭的一个:
主席这个位子,是老黄走了才有的,
宣布选帅的信,是他亲手发的。
他现在改口,等于承认自己上任第一周就办错了事。
所以记住这个人:
他手里不光有一票,他还攥着议程。
他不点头,这场会开起来都别扭。
4. 布鲁克·西韦尔,持股250万股,审计委员会主席。
琼斯在Synopsys时的老搭档,
是琼斯劝进英伟达的,跟了琼斯28年。
2006年董事会查期权问题,
他就在审计委员会里,
最后的结论是管理层诚信没问题,老黄留任。
他这辈子,已经给老黄签过一次清白。
琼斯往哪边走,他大概率往哪边走。
这4票是基本盘。
但要看清:琼斯那票带条件,
所以基本盘不是铁板,是3票加1票候选。
5. 斯蒂芬·尼尔,首席独立董事,治理委员会主席。
77岁,Cooley律所前CEO,诉讼律师出身,
一辈子给董事会当治理顾问。
这轮独立调查就是他这套班子搭的:
请Wachtell律所、请前联邦检察官Joon Kim来查。
他持股只有18万股,
他真正的资产是“敢管创始人”的名声。
让他翻盘,等于让他自己砸自己的招牌。
他最在乎的还不是出轨,
是老黄有没有对董事会说过谎。
这一条洗不清,他那票想都不要想。
6. 苏珊·约翰逊,国安委员会主席。
高盛前副主席,今年7月才进董事会,
是10个人里跟老黄交情最浅的,
持股只有2496股。
11月17号董事会新设国家安全与出口管制委员会,
主席就是她。
这个委员会就是董事会摆出来的姿态:
先把合规管起来,没打算请人回来。
她投赞成,等于亲手拆自己刚挂牌的委员会。
10票里,她是最难翻的一票。
7. 梅丽莎·洛拉,前Taco Bell国际总裁。
持股1799股,全场最少。
别小看她,她有前科:
2006年在KB Home,
她是调查CEO期权问题的三人小组成员,
结论出来当天,那位CEO就走人了。
她干过“查完把CEO送走”这件事,
而且现在在另一家公司也管治理。
这种人,天生站在调查这一边。
8. 唐·哈德森,薪酬委员会主席。
前百事北美CEO、NFL首席营销官,
持股36.8万股。
她管的是高管薪酬和高管行为规范,
老黄跟直属下属那段关系,
正好撞在她管的口径上。
所以她现在站在反对派。
但她是反对派里最软的一票:
她不在调查核心里,也不在国安委员会里,
离送走老黄的那套程序最远。
真要拆反对派,先拆她。
9. 约翰·达比里,46岁,加州理工教授。
全场最年轻,比第二年轻的小15岁。
国家科学奖章得主,给总统当过科技顾问。
他是10个人里唯一真正懂技术的人。
外面专家给这届董事会打“约F分”,
理由就是五个VC加一个高盛,没人懂业务,
他是唯一的例外,他自己心里最清楚。
但他现在坐在约翰逊的国安委员会里,
机构身份又把他往反对那边推。
这个人不用讲交情,也不用讲股价,
他只认一样东西:证据。
10. 阿尔蒂·沙阿,统计学博士,前礼来制药CIO。
董事会里的网络安全和数据专家,
持股2.5万股,没当任何委员会主席,
这几天所有动作里都没有她。
这种票有个特点:不领头,不出头,
但屋里有5票的时候,她不会做唯一的异类;
屋里只有2票的时候,她也不会跟。
说白了,她是全场最标准的那张“第6票”。
三、6票,到底怎么凑?
标准答案很简单:
同意派4票,加上学术派2票,正好6票。
反对派4票全不动,决议照样通过。
所以这场仗的胜负手,
不是去掰尼尔和约翰逊那两块铁板,
是把达比里和沙阿这两个读书人说服。
说服他们只需要给两样东西:
第一,调查报告在国安问题上给结论,
哪怕只是一句“无证据显示机密受损”,
这句话董事会11月8号自己就说过,
现在需要调查把它坐实。
第二,12月1号国会闭门问询别爆新雷。
这两样齐了,
他们投的就不是人情票,是证据票,
回学校、回学界,都交代得过去。
但还有一个变数,就是琼斯。
如果琼斯顾面子,他那票掉队,
同意派就只剩3票,
加学术派2票是5票,还差1票。
这时候就必须去拆反对派,
拆最软的哈德森,
用的方案叫“带镣铐的回归”:
老黄只回CEO,不回董事席;
国安委员会常设,出口管制不经他一个人的手;
跟下属那件事单独处置;
调查继续查,回归不等于结案。
这套方案是给哈德森和尼尔留的台阶:
你们投的不是给老黄免罪,
是给他套上笼头再用他。
最后看时间。
能把票推过线的,只有四件事,按顺序来:
调查的阶段性结论,
12月1号的国会问询,
财报之后核心人才还走不走、客户的单子还签不签,
还有贝莱德和先锋私下跟董事们怎么说。
两家合计14.74%,
他们不用公开站队,
只要让董事们知道改选时不追责,
摇摆的人,腰就软一半。
说到底,
决定黄仁勋能不能回去的,
不是请愿书上那19万个名字,
不是特朗普那句“不介意”,
也不是马斯克那一签。
是两个手里只有4万股的读书人,
在证据和风险之间,
最后把手举不举起来。
6票凑齐那天,
英伟达的8-K会比任何请愿都短:
一页纸,人就回来了。
98
$NVDA uhm. I like it
Why some Board members want Jensen back as CEO despite the new Chaiman saying he is not considering the idea.
IMHO, I think Jensen was forced to resign as probably there were some "evidence" that were sent by someone powerful we will call China Hawk (CH) to the Board about Jensen or his daughter Madison that was responsible for Asia sales. The CH may want to persecute the daughter in order to make it very painful for Jensen, that was enough to force Jensen to resign immediately.
Jensen knew he was irreplaceable as he has 60 direct reports and the pace of innovation in Nvidia is unrelenting as Nvidia needs to be at least 2 generations ahead of his competitors to command a 75% monopolistic markup, and use the strong balance sheet to grow the AI ecosystem via financing startups.
Jensen knew all the potential candidates that the the Board is considering as they are his friends. All of the candidates told Jensen they don't want the CEO job at Nvidia as it is a hot seat as half the global market in China for AI cannot be addressed and the CH wants a trusted Chairman that can review and block international sales of Nvidia chips if it can be diverted to China on national security ground. Moreover, half of Nvidia's researchers are ethnic Chinese and the national security risks need to be addressed. So basically, Nvidia is being nationalized indirectly, so under the new regime it will be a repeat of Boeing or Intel saga again - slow descend into oblivion.
In addition, with a new CEO at the helm of Nvidia most of the Taiwanese ODMs that Jensen work with will all want a strict formal contract with upfront deposits for all commitments Jensen has made with them based on a handshake. Nvidia doesn't have a written contract with TSMC as Jensen and TSMC founder Morris Chang are pals and they have been working together for 30+ years.
Once all the key employees of Jensen resign - the share price of Nvidia will collapse and it will bring down the whole AI industry in the US. Remember all the key employees of Jensen are millionaires already from their stock holdings in Nvidia. So they can afford to resign and retire if they want to. The US government is afraid of that and Jensen doesn't want that either as it will destroy the AI industry that he created.
semafor.com/article/11/17/20…
126
$NVDA what a man!
Over the past week, I’ve been overwhelmed by the love and support of friends, industry colleagues, and people I've never met. Thank you to everyone who has shown kindness to my family and me. It means the world to me.
I came to the United States 53 years ago, and becoming an American citizen is one of the greatest gifts and proudest moments of my life. NVIDIA has been my life’s work. Building it into the company it is today alongside my colleagues has been a privilege and an honor. Nowhere but in America could a company like NVIDIA be possible. I love our country, and I love NVIDIA.
I did not live up to the standards expected of everyone at NVIDIA, and I have made serious mistakes in my personal life. I created problems for the Board that I deeply regret. I own my mistakes completely, and I am committed to cooperating with the Board’s independent investigation.
Since my departure, I’ve seen an outpouring of calls from NVIDIA’s employees, investors, business partners, and customers for me to return as CEO. Many continue to reach out to me directly as the company navigates complex technology, market, competitive, and geopolitical dynamics. NVIDIA is a once-in-a-generation company. If the Board of Directors decides that my return is in the best interest of our shareholders, our employees, the company, and America, I would be honored to answer these calls and return as CEO.
Thank you again to everyone who has shared their good wishes. I am profoundly humbled by your support. To my family: I love you, and I will spend the rest of my life being worthy of yours.
Jensen
121
Over the past week, I’ve been overwhelmed by the love and support of friends, industry colleagues, and people I've never met. Thank you to everyone who has shown kindness to my family and me. It means the world to me.
I came to the United States 53 years ago, and becoming an American citizen is one of the greatest gifts and proudest moments of my life. NVIDIA has been my life’s work. Building it into the company it is today alongside my colleagues has been a privilege and an honor. Nowhere but in America could a company like NVIDIA be possible. I love our country, and I love NVIDIA.
I did not live up to the standards expected of everyone at NVIDIA, and I have made serious mistakes in my personal life. I created problems for the Board that I deeply regret. I own my mistakes completely, and I am committed to cooperating with the Board’s independent investigation.
Since my departure, I’ve seen an outpouring of calls from NVIDIA’s employees, investors, business partners, and customers for me to return as CEO. Many continue to reach out to me directly as the company navigates complex technology, market, competitive, and geopolitical dynamics. NVIDIA is a once-in-a-generation company. If the Board of Directors decides that my return is in the best interest of our shareholders, our employees, the company, and America, I would be honored to answer these calls and return as CEO.
Thank you again to everyone who has shared their good wishes. I am profoundly humbled by your support. To my family: I love you, and I will spend the rest of my life being worthy of yours.
Jensen
109
$cadl
The filing delayed for 7 mos, frustrating, but not canceled
The price may be yoyo in $4-$7 for 5 mos it will then shoot up big to $25 in june-july 2027
It seems to be inevitable they will file one day
Add more but in no hurry
Candel $CADL plans to file its prostate cancer BLA this quarter on a Phase 3 that beat placebo on disease-free survival, HR 0.70. Its overall survival HR is 1.18, not significant, and no Candel release I read reports it. Candel's SITC late-breaker is shedding and immune data.
SITC (@sitcancer) put out its late-breaking abstract titles on Oct 29, and Candel's abstract 1172 is the one that sent me back to the footnotes of the trial its BLA rests on. So this piece tries to answer one question. What will the FDA actually be weighing when the filing goes in, and does the Nov 7 poster change any of it?
WHAT THE DRUG IS
Aglatimagene besadenovec (CAN-2409) is an adenovirus that can't replicate, built to carry a herpes virus gene, thymidine kinase, into the tumor. Each man gets three ultrasound-guided injections into the prostate, at least 14 days apart and timed around radiation, and takes valacyclovir, a common antiviral pill, for 14 days after each one. In the cells the virus reaches, the enzyme turns valacyclovir into a nucleotide analog that gets built into DNA and kills the cell. Candel's bet is that cells dying this way also show the immune system what to attack, which is why it keeps bringing immune data to meetings like SITC.
THE NUMBERS THAT DECIDE THE BLA (chart 1)
The pivotal trial, PrTK03, was published in The Lancet Oncology (@TheLancetOncol) in June. Between February 2012 and September 2021 it randomized 745 men with intermediate-risk (85%) or high-risk (15%) localized prostate cancer 2:1, double-blind. Everyone got radiation and valacyclovir, and the control arm got placebo injections. It ran under a Special Protocol Assessment agreed with the FDA.
• Disease-free survival (DFS), the primary endpoint, HR 0.70 (95% CI 0.52–0.94), p=0.016, at a median follow-up of 50.3 months, with events in 23% of men on aglatimagene and 31% on placebo
• Prostate-cancer-specific DFS, a predefined secondary endpoint, HR 0.62 (0.44–0.87)
• Tumor-free biopsies at about two years, 80% (167 of 209) vs 63% (62 of 98), in what the paper calls a post-hoc blinded review that left out six indeterminate biopsies
• PSA down to 0.2 ng/mL or lower, 67% vs 59%
• Grade 3 or worse adverse events, 8% vs 7%
I want to give this its due. It's a double-blind, placebo-controlled Phase 3, two masked central readers had to confirm tumor before a biopsy counted as positive, and the safety numbers look like the control arm's. The biopsies and the PSA numbers point the same way. That's a real result, and I'm not going to pretend otherwise.
WHAT COUNTS AS A RECURRENCE (chart 2)
This is the footnote I read first. The paper defines DFS as the time to "local (including positive biopsy) or regional failure, distant metastases, or all-cause death." The protocol called for a biopsy about two years after radiation, and tumor in that biopsy counted. Candel's own December 2024 topline filing said it plainly, the primary endpoint "included the evaluation of post-treatment biopsies, performed at two years from the end of radiation." A rising PSA on its own isn't on the list, and the paper says freedom from biochemical failure wasn't analyzed "due to the small number of events."
That stopped me. The trial counted 189 DFS events (113 plus 76), yet too few PSA failures to analyze. As I understand routine care, men are followed with PSA tests after radiation, and a biopsy usually comes only once PSA rises. So this endpoint counts something ordinary follow-up doesn't go looking for. 451 of the 745 men (61%) had the 2-year biopsy, 313 (42%) in the 22–26-month window. In that window, by my arithmetic from the paper's tumor-free rates, tumor was found in 42 of 209 evaluable men on aglatimagene (20%) and 36 of 98 on placebo (37%).
Here's the number that bothers me. Prostate-cancer events ran 17% vs 25%, a gap of about 8 points. If each of those positive biopsies was scored as an event, as the definition allows, they alone would make up about 6 of the 8 points (42 is 8.5% of 496, 36 is 14.5% of 249). That's my arithmetic, and it rests on an assumption the paper doesn't let me check, because it doesn't break the events down by type, and some of those men may have failed in other ways too. But it's why the first thing I'd ask Candel for is how many DFS events were a positive biopsy and nothing else.
The effect is also smaller than the trial was built to find. The sample-size plan assumed about 98 events would give 90% power to detect a hazard ratio of 0.5. The analysis had those 189 events and found 0.70.
WHAT THE RELEASES LEAVE OUT (chart 1)
Overall survival. In the paper it's HR 1.18 (95% CI 0.64–2.15), p=0.59, with 36 deaths (7%) on aglatimagene and 15 (6%) on placebo, one of them from prostate cancer in each arm. The most common cause of death on the drug arm was infection, 8, against 1 on placebo. The masked adjudicators attributed no death to the drug, the interval is wide, and I'm not reading harm into it. I wouldn't expect a survival benefit at four years in this disease anyway, and the authors say showing one would take about ten years of follow-up.
What I can't square is the presentation. I read five Candel releases on this trial, from the December 2024 topline to two on Sept 30, and none of them reports overall survival or all-cause deaths. The two updates with longer follow-up, in May and September, lead with prostate-cancer-specific DFS, HR 0.61 at 58 months and 0.59 in intermediate-risk men. That secondary endpoint leaves out deaths not caused by prostate cancer, and those ran a little higher on the drug. By my arithmetic from the event counts, 31 of the primary endpoint's events on aglatimagene and 14 on placebo were deaths not tied to prostate cancer (6.3% vs 5.6%), which is why the secondary reads better than the primary, 0.62 vs 0.70 in the paper. The May update didn't refresh the primary endpoint at all.
The later signals are small. At 58 months, metastases were 1.6% (8 of 496) vs 2.8% (7 of 249), HR 0.58 (0.21–1.59), and time to biochemical failure was HR 0.72 (0.40–1.31). Both lean the right way, and neither interval rules out no effect. The 90% improvement in time to metastasis that Candel highlighted for intermediate-risk men rests on 1 metastasis against 5 (HR 0.1, 95% CI 0.01–0.85).
WHAT THE LATE-BREAKER IS (chart 3)
Abstract 1172 is titled "Longitudinal immune profiling in the PrTK05 trial of aglatimagene besadenovec plus valacyclovir with radiation therapy for localized intermediate-risk prostate cancer." Candel says the poster adds biodistribution and viral-shedding data. The text goes public on Nov 6 at 9 a.m. ET, and the poster goes up on Nov 7, presented by Candel's chief scientific officer.
PrTK05 isn't a second efficacy trial. Its registry record calls it a Phase 2a "biomarker study", open-label and not randomized, planned for 45 men with favorable intermediate-risk disease, 30 getting the drug with radiation and 15 radiation alone. Its primary endpoint is viral DNA in urine, blood and semen up to 5 months after the last injection. It started in October 2025, it's still recruiting, and its estimated primary completion is February 2027. On Sept 30, Candel showed T-cell expansion in the blood of 13 treated men against 6 controls, and said the shedding data "have been compiled for inclusion" in the BLA.
So I read the poster as a box a gene therapy filing has to tick (the FDA has had guidance on shedding studies since 2015), not as a readout. It still matters. Jefferies, starting coverage on Oct 22, said the key near-term risk had shifted to finishing manufacturing work and the PrTK05 study, as the Investing news site reported the note. When the text goes up I'll be looking for three things:
• how many treated men the data cover, against the 30 planned
• how long viral DNA stays detectable in urine and semen, and whether any turns up in blood
• whether the immune changes seen in 13 men hold in more
I'm not expecting anything that changes the efficacy case. What I'd want explained is a filing going in this quarter while the study feeding its shedding data is still recruiting. That may be routine for shedding data, but I haven't seen Candel say how many men the BLA's data cover.
THE REALITY CHECK
• It's an old trial. Enrolment ran from 2012 to 2021. Of the 711 men treated, 72% got standard fractionation (median 78 Gy), and moderate hypofractionation was allowed only after a 2019 amendment (25% got it). I'd want to know how three injections and six weeks of valacyclovir fit the shorter radiation courses that are common now
• High-risk men were 15% of the trial, and only 18 of 105 treated high-risk men got more than six months of hormone therapy, a gap the authors flag themselves. Candel plans to file for intermediate- to high-risk disease
• Hormone therapy was optional, and 49% got a short course. Candel says exploratory analyses suggest benefit either way
• The SPA is real support, because the FDA agreed to the design. Candel's own filings also say it covers "certain aspects of the study design" and "does not guarantee any particular outcome from regulatory review"
• The endpoint academic groups have validated as a stand-in for survival in localized prostate cancer, in the ICECaP work, is metastasis-free survival. These data are too immature to show it
MY READ
The market will trade on the filing, whether it goes in this quarter and whether the FDA accepts it. The label will be decided on whether the FDA counts a gain that seems to sit mostly in a 2-year biopsy as clinical benefit, in a trial with too few PSA failures to analyze and a survival result none of the five releases I read has shown. My read is that the risks Jefferies named, manufacturing and PrTK05, are ones Candel controls. The endpoint is the one it doesn't.
What would change my mind:
1. An event breakdown showing most of the DFS gap isn't biopsies alone
2. The primary endpoint and overall survival updated at 58 months, with the survival gap closing
3. The FDA accepting the filing without asking for longer follow-up
A question for radiation oncologists and urologists. If a protocol biopsy finds tumor two years after radiation in a man whose PSA hasn't risen, what do you actually do with that result? Your answer decides how much this endpoint is worth to me.
Not investment advice. Not medical advice.
Sources: SITC's Oct 29 release and press policy; Candel's releases (Dec 11, 2024, and May 15, June 2, Sept 30 and Oct 29, 2026) and SEC filings; The Lancet Oncology (DeWeese et al., June 2026); the NIH trial registry; the FDA's shedding-study guidance; ICECaP-2 in Annals of Oncology; Jefferies' initiation as reported by the Investing news site.
#SITC26 #ProstateCancer #ImmunoOncology #GeneTherapy #ClinicalTrials #Biotech
236
$OPEN
a tough Q4 ahead, reporting in Feb.
My Spec:
1. R/S in April
2. Take it private, buy back @ $0.2-$0.8 quietly
3. Convert WT into shrs in Fri to stabilize the army not to dump @ $0.5-$0.8 prematurely
Look at the hottest Manhattan RE in Oct.
Big slow down
$open
2nd last gap s deemed filled @$1.05
The last unfilled gap:$0.80-$0.90
Aftr that gets filled, no technical requirement going down further
but driven by fundmntls
Carrie's low: $0.52
So Kaz's low d be <$0.5
But
What if Kaz gambles w/buyback @ $0.8-?
WO a 300m+ vol,25%+ day
387
$open
2nd last gap s deemed filled @$1.05
The last unfilled gap:$0.80-$0.90
Aftr that gets filled, no technical requirement going down further
but driven by fundmntls
Carrie's low: $0.52
So Kaz's low d be <$0.5
But
What if Kaz gambles w/buyback @ $0.8-?
WO a 300m+ vol,25%+ day
$OPEN
2 more gaps to fill $1.2, $0.8
They ll be filled in days/wks/mos aftr a pot technical rebound when gap@ $1.4-$1.6 s filled
I was an expert ftelling its ascent
Now its descent
upset by my losses, their reckless diluiton talking fail-delivery of$1.5B revs/Q in nxt 3 Qtrs
$NVDA
totally agree @lexfridman
I wrote a note to my group aftr hearing the board rumors n Jensen resignation, in Casablanca
I think chances r months later they d have to recall Jensen to $NVDA
Among human fallacies, kill the lesser, protect the greatest: creater builder maker
NVIDIA letting Jensen go is a huge mistake, for America and for humanity. It's Apple firing Steve Jobs all over again, but much bigger, given the role of AI in defining the future of our world.
I've been keeping quiet on this out of respect for Jensen's family and team, who I've met and who are amazing humans, and because I personally hate infidelity. So my heart goes out to them in this difficult personal family moment.
But I can also say that Jensen is human, and makes mistakes like all of us do. Not that I matter at all, but I've known Jensen for a long time and have gotten the chance to spend a lot of time with him, behind the scenes, away from mics and cameras. I have seen him show kindness, humility, care to everyone around him, including strangers, including from the poorest most struggling parts of society, treating all the same with the same thoughtfulness and attention, because they are fellow humans and not because he has something to gain from them. That shows rare character, to maintain humility and humanity through all of it.
Another data point is what people who know him well have said privately to me about Jensen over the years. I've never had anyone tell me anything but how awesome he is or how much they love him. Probably over a thousand people at this point. This includes hundreds of engineers, CEOs, colleagues, friends, etc.
Also, since there was some spy talk. Jensen is as proud an American as it gets. I'm in shock frankly at all of this, including the mass hysteria around it. I love America, and I think NVIDIA letting Jensen go is terrible for America.
I stand with Jensen.
Love you all ❤️
199
Jensen Huang and the Nvidia board just made a massive mistake.
He should not have resigned.
The board should have taken the time to conduct a thorough investigation, consult with shareholders, and carefully evaluate the long-term implications of this decision.
There is no clear replacement for Jensen Huang, and we believe his departure will ultimately be a net negative for Nvidia, $NVDA, and its shareholders.
This will go down as the most costly mistake of the AI Revolution.
118
$NVDA true
161
$spy $nvda yes its not sainthood that creates produces generates invents makes the best ai chips of our times @saranormous
.@JensenHuang is one of the most extraordinary entrepreneurs of all time. He’s bent the arc of technological progress, and the growth engine of the American economy rests on the shoulders of the company he built.
Sadly, greatness doesn’t guarantee goodness. It’s disappointing.
The Economist says “no one is irreplaceable.” They are very wrong. A founder who has spent 30 years building such a unique company so capably has earned the presumption that he should keep leading it.
More importantly, our competitors and adversaries will not wait for us to find “another Jensen.”
The board is getting to the bottom of the national security and judgement questions. Depending on the answers, I expect most shareholders would want him to continue leading.
We should demand loyalty and accountability, but sainthood cannot be the price of admission to leadership. or to Team America.
215
Our message to Nvidia's board:
Do not fire Jensen Huang.
There is no clear replacement for Jensen Huang. We are confident that his departure would ultimately be a net negative for Nvidia, its shareholders, and the AI Revolution.
First, take a look at the data. History also suggests that removing a successful CEO will come with a significant cost.
A study of 187 forced CEO departures from S&P 1500 companies found that removing outperforming CEOs resulted in negative long-term stock returns. This case would be no different, in our view.
Jensen Huang is the definition of an outperforming CEO. Nvidia's board must not make a decision in the heat of the moment.
The board should take the time to conduct a thorough investigation and consult with shareholders, with a strong emphasis on the latter.
Quite literally, Nvidia's board should convene a special shareholder meeting and hold an advisory vote on this decision. This is the most consequential CEO controversy in world history. Shareholders deserve a say.
In addition, Nvidia's stock, $NVDA, is now down -35% in 26 trading days, nearly half of which is a result of the recent scandal.
We believe Jensen Huang's potential removal as CEO is now ~80% priced in.
Why take an action with massive downside potential when the market has already priced in much of that risk?
The downside of retaining Huang may be limited, while the potential upside is tremendous.
Lastly, history shows that retaining Jensen Huang could still lead to a favorable outcome. In 2019, Amazon retained Jeff Bezos as CEO after his extramarital affair became public, and the company's stock subsequently surged +108% by 2021.
Personal misconduct should not be ignored, but it must also be distinguished from corporate wrongdoing and weighed against the consequences of removing an executive who is instrumental to the company's success.
We believe Jensen Huang is an irreplaceable part of Nvidia and the AI Revolution more broadly.
Once the dust settles, firing Jensen Huang would prove to be a costly mistake.
It is time to pause and consult your shareholders.
147
$nvda agree totally
An alert:
@JensenHuang is human. And he is an incredible human. Even incredible humans make mistakes.
He takes full responsibility as he should.
We should all support him and his family.
Onward.
196
$open
losing $220m /Q
having $590m real assets they can last another 3qtrs
They accumulated $2.5B inv
crazy crazy
had to sell at huge losses in this mrkt cndtn
This Canadian gambler gambled away american kids $1.6B dlrs
Gave away /diluted your shrs crazily
$OPEN Going down to zero? They raised about $650M in zero-coupon convertible notes in August… netting roughly $440M after buying back $158M of stock. Ok… Then they turned around and lost $218M in Q3 alone.
Most of the cash burn is from ramping inventory hard, they’re buying way more homes than they’re selling right now… inventory is up to $2.6B. They still have around $910M in cash, but equity is only about $590M against a big pile of inventory-backed debt. So what the stock should be?
They’ve been losing money for years and management admits they’re behind on the “profitable by year-end” goal. At $1.40 the stock is already pricing in a clean turnaround. If that doesn’t happen, this can easily go a lot lower, practically close to nothing. Are they going to take this junk private?
259
$CIFR $IREN $INTC $FLNC $EOSE $OPEN $NVTS $SMCI $SNDK $BE
$NBIS
Losses break your hearts
damaging your health
Let's recoup losses
atleast lose wo pains&break your heart by
creating
building
making
designing
developing
A Powerful S0dte
Printing for you
While you reading books
$spy spy Turned neutral from bearish whole morning at 13:10pm coinciding with resistance $756.5 ema 50 on 15 m chart
So i belive breakout of that wma50 line will make all gamma readings positive and bullish
So power hour may run big
1
338
$OPEN
2 more gaps to fill $1.2, $0.8
They ll be filled in days/wks/mos aftr a pot technical rebound when gap@ $1.4-$1.6 s filled
I was an expert ftelling its ascent
Now its descent
upset by my losses, their reckless diluiton talking fail-delivery of$1.5B revs/Q in nxt 3 Qtrs
$open another one scam account I tried to correct its misleading bull numbers on $open.
This is scary. Potential Legal issue here
$open if i keep silent i would mislead young innocent investors. My data may be 1-2mos ago. Kaz already used up $1.65B he got frm diluting to $0.9B or less 1-2 mos ago, now quick ratio d be <1
If you r still bullish
Be ready for what u desired for $0.5
Dont mislead
215
$open @BertrandPirel
No misleading pls
these tutes bought n short it for hedging the same time
So does capped call banker/ notesholders
U should ask rough questn:
$158m paid to whom to retire those shares?
Was Kaz incld in offering the shares n got $ frm you
the sharholder?
203



























